# A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

> **NCT03936959** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 10 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** LY3434172

## Key facts

- **NCT ID:** NCT03936959
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-24
- **Primary completion:** 2020-03-30
- **Final completion:** 2021-04-29
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Study did not achieve its primary objective due to early termination of the study
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936959, "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03936959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*